Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Study Participants Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

NCT03928327
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788, Itraconazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

NCT06003777
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06954522, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

NCT04016077
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
PF-06651600 30 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants

NCT01762839
View directory record Official record
Conditions
Healthy
Interventions
Single-Dose IV Oritavancin Diphosphate, Placebo, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

NCT05841277
View directory record Official record
Conditions
Renal Insufficiency, Healthy
Interventions
LY3819469
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134
View directory record Official record
Conditions
HIV Infections
Interventions
TRIUMEQ, DOVATO
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

NCT06704763
View directory record Official record
Conditions
Healthy
Interventions
Orforglipron, Midazolam, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

NCT03758339
View directory record Official record
Conditions
Healthy
Interventions
tucatinib
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

NCT05409911
View directory record Official record
Conditions
Hepatic Impairment
Interventions
S-217622
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3478045 in Healthy Participants

NCT04270370
View directory record Official record
Conditions
Healthy
Interventions
LY3478045, Placebo, Atorvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

NCT07578636
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
Oral [14C] PF-07799544, Oral Unlabeled PF-07799544, IV [14C] PF-07799544
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

NCT06360211
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions
BAY2927088, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT02754830
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 23, 2026, 12:39 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

NCT06809400
View directory record Official record
Conditions
Parkinson Disease
Interventions
LY4006896, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 85 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
11
States / cities
Los Alamitos, California • Maitland, Florida • Naples, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

NCT05202145
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Cyclosporine, Tacrolimus, MMF
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Probing the Role of Feature Dimension Maps in Visual Cognition: Impact of Salience Level (Eye-tracking Follow-up Study)

NCT06852534
View directory record Official record
Conditions
Basic Science: Visual Attention in Healthy Participants, Attention
Interventions
Stimulus properties: salience-defining feature, Stimulus properties: magnitude of salience
Other
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

NCT02759107
View directory record Official record
Conditions
Healthy, Type 2 Diabetes Mellitus (T2DM)
Interventions
Tirzepatide, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

TAK-935 Multiple Rising Dose Study in Healthy Participants

NCT02539134
View directory record Official record
Conditions
Epilepsy
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
LY3502970
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

NCT07248839
View directory record Official record
Conditions
Healthy Volunteers, Hepatic Impairment
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

NCT06148181
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-141, Placebo for ABBV-141
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

NCT02074800
View directory record Official record
Conditions
Healthy
Interventions
CNTO 328 (Sp2/0-derived), CNTO 328 (CHO-derived), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Sep 23, 2026, 12:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

NCT03762928
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06651600, midazolam, efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 23, 2026, 12:39 PM EDT